Prognostic analysis and identification of M7G immune-related genes in lung squamous cell carcinoma
BackgroundIn recent years, the clinical application of targeted therapies and immunotherapy has significantly improved survival outcomes for patients with lung adenocarcinomas(LUAD). However, due to fewer mutations, lung squamous cell carcinomas(LUSC) shows limited efficacy with targeted and immunot...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1515838/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850025472320077824 |
|---|---|
| author | Li Wenhui Li Wenhui Wu Nan Wu Nan Han Jiayi Xu Ye He Chunyu Li Zhongzhou Lei Hongtao Tian Hui |
| author_facet | Li Wenhui Li Wenhui Wu Nan Wu Nan Han Jiayi Xu Ye He Chunyu Li Zhongzhou Lei Hongtao Tian Hui |
| author_sort | Li Wenhui |
| collection | DOAJ |
| description | BackgroundIn recent years, the clinical application of targeted therapies and immunotherapy has significantly improved survival outcomes for patients with lung adenocarcinomas(LUAD). However, due to fewer mutations, lung squamous cell carcinomas(LUSC) shows limited efficacy with targeted and immunotherapy, resulting in a notably lower 5-year survival rate compared to lung adenocarcinoma. The m7G modification plays an important role in tumorigenesis, progression, immune evasion, and therapeutic response. This study aims to develop a novel scoring system based on m7G modification and immune status to clinically predict the prognosis of patients with LUSC and to provide new therapeutic targets.MethodsIn this study, we utilized RNA-seq data from the TCGA-LUSC database as the training set and GSE50081 from the GEO database as the validation set. Immunotherapy data were obtained from the IMMPORT database, and m7G data from previous research. Using bioinformatics, we developed a prognostic model for LUSC based on m7G pathway-related immune gene characteristics. We analyzed the correlation between the prognostic model and clinical pathological features of LUSC, as well as the model’s independent prognostic capability. Subsequently, patients were divided into high-risk and low-risk groups, and we examined the differences in enriched pathways, immune cell infiltration correlations, and drug sensitivity between the two groups.ResultsThe m7G immune-related genes FGA, CSF3R, and ORM1 increase the survival risk in patients with lung squamous cell carcinoma, whereas NTS exerts a protective effect. The prognostic risk model for lung squamous cell carcinoma (LUSC) based on m7G immune-related gene expression demonstrates that the overall survival of the high-risk group is significantly poorer than that of the low-risk group.ConclusionThe risk model developed based on m7G immune-related genes can help predict the clinical prognosis of LUSC patients and guide treatment decisions. |
| format | Article |
| id | doaj-art-ded85c56916f4b88a1bd57d5c3295fb3 |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-ded85c56916f4b88a1bd57d5c3295fb32025-08-20T03:00:50ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-03-011610.3389/fimmu.2025.15158381515838Prognostic analysis and identification of M7G immune-related genes in lung squamous cell carcinomaLi Wenhui0Li Wenhui1Wu Nan2Wu Nan3Han Jiayi4Xu Ye5He Chunyu6Li Zhongzhou7Lei Hongtao8Tian Hui9Department of Radiation Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, ChinaDepartment of Radiation Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, ChinaRespiratory Intensive Care Unit, The First Affiliated Hospital of Kunming Medical University, Kunming, ChinaRespiratory Intensive Care Unit, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, ChinaDepartment of Operations Management, The First Affiliated Hospital of Kunming Medical University, Kunming, ChinaInstitute of Medicine and Nursing, Hubei University of Medicine, Shiyan, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, ChinaSchool of Public Health, Kunming Medical University, Kunming, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, ChinaBackgroundIn recent years, the clinical application of targeted therapies and immunotherapy has significantly improved survival outcomes for patients with lung adenocarcinomas(LUAD). However, due to fewer mutations, lung squamous cell carcinomas(LUSC) shows limited efficacy with targeted and immunotherapy, resulting in a notably lower 5-year survival rate compared to lung adenocarcinoma. The m7G modification plays an important role in tumorigenesis, progression, immune evasion, and therapeutic response. This study aims to develop a novel scoring system based on m7G modification and immune status to clinically predict the prognosis of patients with LUSC and to provide new therapeutic targets.MethodsIn this study, we utilized RNA-seq data from the TCGA-LUSC database as the training set and GSE50081 from the GEO database as the validation set. Immunotherapy data were obtained from the IMMPORT database, and m7G data from previous research. Using bioinformatics, we developed a prognostic model for LUSC based on m7G pathway-related immune gene characteristics. We analyzed the correlation between the prognostic model and clinical pathological features of LUSC, as well as the model’s independent prognostic capability. Subsequently, patients were divided into high-risk and low-risk groups, and we examined the differences in enriched pathways, immune cell infiltration correlations, and drug sensitivity between the two groups.ResultsThe m7G immune-related genes FGA, CSF3R, and ORM1 increase the survival risk in patients with lung squamous cell carcinoma, whereas NTS exerts a protective effect. The prognostic risk model for lung squamous cell carcinoma (LUSC) based on m7G immune-related gene expression demonstrates that the overall survival of the high-risk group is significantly poorer than that of the low-risk group.ConclusionThe risk model developed based on m7G immune-related genes can help predict the clinical prognosis of LUSC patients and guide treatment decisions.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1515838/fullm7Glung squamous cell carcinomas (LUSC)immune-related genesprognosticrisk model |
| spellingShingle | Li Wenhui Li Wenhui Wu Nan Wu Nan Han Jiayi Xu Ye He Chunyu Li Zhongzhou Lei Hongtao Tian Hui Prognostic analysis and identification of M7G immune-related genes in lung squamous cell carcinoma Frontiers in Immunology m7G lung squamous cell carcinomas (LUSC) immune-related genes prognostic risk model |
| title | Prognostic analysis and identification of M7G immune-related genes in lung squamous cell carcinoma |
| title_full | Prognostic analysis and identification of M7G immune-related genes in lung squamous cell carcinoma |
| title_fullStr | Prognostic analysis and identification of M7G immune-related genes in lung squamous cell carcinoma |
| title_full_unstemmed | Prognostic analysis and identification of M7G immune-related genes in lung squamous cell carcinoma |
| title_short | Prognostic analysis and identification of M7G immune-related genes in lung squamous cell carcinoma |
| title_sort | prognostic analysis and identification of m7g immune related genes in lung squamous cell carcinoma |
| topic | m7G lung squamous cell carcinomas (LUSC) immune-related genes prognostic risk model |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1515838/full |
| work_keys_str_mv | AT liwenhui prognosticanalysisandidentificationofm7gimmunerelatedgenesinlungsquamouscellcarcinoma AT liwenhui prognosticanalysisandidentificationofm7gimmunerelatedgenesinlungsquamouscellcarcinoma AT wunan prognosticanalysisandidentificationofm7gimmunerelatedgenesinlungsquamouscellcarcinoma AT wunan prognosticanalysisandidentificationofm7gimmunerelatedgenesinlungsquamouscellcarcinoma AT hanjiayi prognosticanalysisandidentificationofm7gimmunerelatedgenesinlungsquamouscellcarcinoma AT xuye prognosticanalysisandidentificationofm7gimmunerelatedgenesinlungsquamouscellcarcinoma AT hechunyu prognosticanalysisandidentificationofm7gimmunerelatedgenesinlungsquamouscellcarcinoma AT lizhongzhou prognosticanalysisandidentificationofm7gimmunerelatedgenesinlungsquamouscellcarcinoma AT leihongtao prognosticanalysisandidentificationofm7gimmunerelatedgenesinlungsquamouscellcarcinoma AT tianhui prognosticanalysisandidentificationofm7gimmunerelatedgenesinlungsquamouscellcarcinoma |